A phase 2 trial of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin has shown it reduces articular cartilage loss in knee OA but the magnitude of effect is of uncertain clinical significance. Published in JAMA, the results from 549 participants in the FORWARD trial showed that six-monthly or 12-monthly intra-articular injections of the recombinant human ...
Mixed results for disease-modifying OA drug sprifermin
By Michael Woodhead
22 Oct 2019